Lam C, Ha K, Hakam A, Shahzad MM. Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism.
Gynecol Oncol Rep 2022;
41:100992. [PMID:
35540026 PMCID:
PMC9079239 DOI:
10.1016/j.gore.2022.100992]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/13/2022] [Revised: 04/25/2022] [Accepted: 04/26/2022] [Indexed: 12/14/2022] Open
Abstract
Management of platinum refractory ovarian cancer is challenging.
Extensive venous thromboembolism precludes anti-angiogenic combination chemotherapy.
Weekly paclitaxel and immune-checkpoint inhibitor combination provides a durable tumor control option.
Collapse